Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study Calvo E et al. Clin Cancer Res 2004 Nov 1;10(21):7112-20 CI-1033, a pan-erbB tyrosine kinase inhibitor Slichenmyer WJ et al Semin Oncol 2001 Oct;28(5 Suppl 16):80-5 The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be